Source: Annual Congress 2010 - Nocturnal cardiology: chronic heart failure, acute chest syndrome, coronary artery disease and collagen vascular disease
Disease area: Pulmonary vascular diseases, Sleep and breathing disorders

Abstract

BACKGROUND: Obstructive sleep apnea syndrome (OSAS) and the metabolic syndrome (MS) are associated with increased cardiovascular risk. Several controlled trials have investigated the influence of CPAP therapy on the metabolic parameters, but the long term CPAP treatment effect was not clearly established yet. The objective of our study was to assess the prevalence of metabolic syndrome in a group of OSAS patients and to determine the effects of 6 months CPAP therapy on the components of metabolic syndrome.
METHODS: We prospectively investigated the prevalence of MS in a group of 334 consecutive patients (255 males, mean age 53.4± 11.4) diagnosed with OSAS. The patients were classified according to their disorders, including hypertension, obesity and dyslipidemia. We performed PSG for diagnosis, CPAP titration and control and analyzed AHI, BMI, systolic and diastolic BP before and after 6 months of CPAP therapy.
RESULTS: In our study group 133 patients (39.82%) presented the criteria for the diagnosis of metabolic syndrome. After 6 months of effective CPAP therapy, we found a significant decrease of the mean BMI (35.87 kg/m2±6.04 to 33.85 kg/m2±5.2), mean systolic (151.17 mmHg±16.11 to 139.10±13.9 mmHg) and diastolic BP (88.23 mmHg±10.5 to 80.65mmHg±7.6) in the group of OSAS patients with MS.
CONCLUSION: The long term effects of CPAP therapy in patients diagnosed with OSAS and MS are more important than in OSAS patients only.

Rating:

Share or cite this content

Citations should be made in the following way:
D. Boisteanu, R. M. Vasiluta, C. E. Mucenica, A. Cernomaz (Iasi, Romania). Long term effects of CPAP therapy in sleep apnea patients with metabolic syndrome. Eur Respir J 2010; 36: Suppl. 54, 911

Member's Comments

No comment yet.

Related content which might interest you: CPAP treatment for sleep apnea syndrome: compliance increases with very long term use Source: Eur Respir J 2005; 26: Suppl. 49, 723s Year: 2005 Effects of long term nCPAP treatment on patients with obstructive sleep apnoea syndrom Source: Eur Respir J 2007; 30: Suppl. 51, 322s Year: 2007 CPAP treatment for obstructive sleep apnoea syndrome after CPAP training term Source: Eur Respir J 2002; 20: Suppl. 38, 102s Year: 2002 CPAP variability in long term follow-up of OSAS (obstructive sleep apnea syndrome) patients Source: Eur Respir J 2006; 28: Suppl. 50, 412s Year: 2006 Glucose-Insulin metabolism in sleep apneoa patients: Effect of long term CPAP treatment Source: Annual Congress 2003 - Systematic inflammation and metabolic disorders in sleep related breathing disorders Year: 2003 The influence of long-term CPAP therapy on metabolic variables in obstructive sleep apnea patients Source: International Congress 2018 – Cardiovascular and metabolic consequences of sleep-disordered breathing Year: 2018 Long-term outcome of nCPAP therapy in sleep apnoea patients Source: Eur Respir J 2004; 24: Suppl. 48, 569s Year: 2004 Possibility of treating patients with obstructive sleep apnea syndrome and nocturnal asystoles using CPAP therapy Source: Annual Congress 2009 - Clinical aspects of sleep apnoea Year: 2009 Pitolisant long term effect in sleepy obstructive sleep apnea patients without CPAP. Source: Virtual Congress 2021 – Advances in therapeutic plans for sleep disordered breathing Year: 2021 Pitolisant long term effect in sleepy obstructive sleep apnea patients with CPAP. Source: Virtual Congress 2021 – Different treatment modalities and impact of comorbidities on sleep disordered breathing Year: 2021 Pitolisant long term effect in sleepy obstructive sleep apnea patients with CPAP Source: Sleep and Breathing Conference 2021 Year: 2021 Pitolisant long term effect in sleepy obstructive sleep apnea patients without CPAP Source: Sleep and Breathing Conference 2021 Year: 2021 Duration of CPAP use in the 1st night of treatment predicts success of therapy in patients with the sleep apnoea syndrome Source: Eur Respir J 2002; 20: Suppl. 38, 100s Year: 2002 Effects of nCPAP treatment on quality of life of patients with obstructive sleep apnoea syndrome Source: Eur Respir J 2006; 28: Suppl. 50, 410s Year: 2006 Indication, compliance and tolerance of CPAP/BiPAP in sleep apnea syndrome in children Source: Annual Congress 2009 - Sleep apnoea across the ages Year: 2009 Effects of CPAP treatment on physical fitness in patients with obstructive sleep apnoea syndrome (OSAS) Source: Eur Respir J 2003; 22: Suppl. 45, 97s Year: 2003 Outcome with CPAP in patients with suspected sleep apnea syndrome Source: Annual Congress 2007 - Sleep apnoea Year: 2007 PAI-uPA system in patients with obstructive sleep apnea syndrome (OSAS) in CPAP treatment Source: Annual Congress 2012 - Cardiovascular disease and sleep-disordered breathing Year: 2012 Night treatment with long acting ß2 agonists in mild COPD patients with sleep apnoea syndrome Source: Eur Respir J 2007; 30: Suppl. 51, 74s Year: 2007 Cardiovascular regulation effects of CPAP therapy in obstructive sleep apnea patients with and without hypertension during daytime Source: Annual Congress 2012 - Metabolic and cardiovascular consequences of OSA II Year: 2012